Heterogeneity for Stem Cell–Related Markers According to Tumor Subtype and Histologic Stage in Breast Cancer

Purpose: To evaluate the expression of stem cell–related markers at the cellular level in human breast tumors of different subtypes and histologic stage. Experimental Design: We performed immunohistochemical analyses of 12 proteins [CD44, CD24, ALDH1, vimentin, osteonectin, EPCR, caveolin 1, connexin 43, cytokeratin 18 (CK18), MUC1, claudin 7, and GATA3] selected based on their differential expression in breast cancer cells with more differentiated and stem cell–like characteristics in 47 cases of invasive ductal carcinoma (IDC) only, 135 cases of IDC with ductal carcinoma in situ (DCIS), 35 cases of DCIS with microinvasion, and 58 cases of pure DCIS. We also analyzed 73 IDCs with adjacent DCIS to determine the differences in the expression of markers by histology within individual tumors. CD44+/CD24− and CD24−/CD24+ cells were detected using double immunohistochemistry. Results: CD44 and EPCR expression was different among the four histologic groups and was lower in invasive compared with in situ tumors, especially in luminal A subtype. The expression of vimentin, osteonectin, connexin 43, ALDH1, CK18, GATA3, and MUC1 differed by tumor subtype in some histologic groups. ALDH1-positive cells were more frequent in basal-like and HER2+ than in luminal tumors. CD44+/CD24− cells were detected in 69% of all tumors with 100% of the basal-like and 52% of HER2+ tumors having some of these cells. Conclusions: Our findings suggest that in breast cancer, the frequency of tumor cells positive for stem cell–like and more differentiated cell markers varies according to tumor subtype and histologic stage. Clin Cancer Res; 16(3); 876–87

[1]  Nicholas J. Wang,et al.  Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. , 2009, Cancer research.

[2]  Jeffrey M. Rosen,et al.  Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features , 2009, Proceedings of the National Academy of Sciences.

[3]  M. Ringnér,et al.  The CD44+/CD24- phenotype is enriched in basal-like breast tumors , 2008, Breast Cancer Research.

[4]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[5]  R. Beroukhim,et al.  Molecular definition of breast tumor heterogeneity. , 2007, Cancer cell.

[6]  L. Beaulieu,et al.  Activated protein C promotes breast cancer cell migration through interactions with EPCR and PAR-1. , 2007, Experimental cell research.

[7]  C. D. Salcido,et al.  Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics , 2008, Breast Cancer Research.

[8]  Charlotte Kuperwasser,et al.  Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy , 2008, Breast Cancer Research.

[9]  J. Sleeman,et al.  CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. , 2005, Cancer research.

[10]  M. Clarke,et al.  Stem Cells and Cancer: Two Faces of Eve , 2006, Cell.

[11]  J. Visvader,et al.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.

[12]  K. Kim,et al.  The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer , 2007, Journal of Clinical Pathology.

[13]  Yi Xiao,et al.  The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. , 2008, The American journal of pathology.

[14]  W. Hahn,et al.  Roots and stems: stem cells in cancer , 2006, Nature Medicine.

[15]  Angel Porgador,et al.  Cell type-specific DNA methylation patterns in the human breast , 2008, Proceedings of the National Academy of Sciences.

[16]  D. Melton,et al.  "Stemness": Transcriptional Profiling of Embryonic and Adult Stem Cells , 2002, Science.

[17]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Elaine Fuchs,et al.  Self-Renewal, Multipotency, and the Existence of Two Cell Populations within an Epithelial Stem Cell Niche , 2004, Cell.

[19]  M. Wicha,et al.  HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion , 2008, Oncogene.

[20]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[21]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[22]  Marco Marra,et al.  Transcriptome analysis of the normal human mammary cell commitment and differentiation process. , 2008, Cell stem cell.

[23]  J. Herman,et al.  Methylation Patterns of the E-cadherin 5′ CpG Island Are Unstable and Reflect the Dynamic, Heterogeneous Loss of E-cadherin Expression during Metastatic Progression* , 2000, The Journal of Biological Chemistry.

[24]  D. Birnbaum,et al.  Cancer Stem Cells in Breast: Current Opinion and Future Challenges , 2008, Pathobiology.

[25]  F. Bertucci,et al.  Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. , 2009, Cancer research.

[26]  I. Giannopoulou,et al.  The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas. , 2008, Human pathology.

[27]  Kornelia Polyak,et al.  Breast Tumor Heterogeneity: Cancer Stem Cells or Clonal Evolution? , 2007, Cell cycle.

[28]  Jean Paul Thiery,et al.  Epithelial-mesenchymal transitions in development and pathologies. , 2003, Current opinion in cell biology.

[29]  Daniel Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[30]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  T. Sørlie,et al.  Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms , 2006, BMC Genomics.

[32]  P. Nowell.  The clonal evolution of tumor cell populations. , 1976, Science.

[33]  Jeffrey M. Rosen,et al.  The Increasing Complexity of the Cancer Stem Cell Paradigm , 2009, Science.

[34]  G. Heppner,et al.  Tumor heterogeneity: biological implications and therapeutic consequences , 2004, Cancer and Metastasis Reviews.

[35]  S. Morrison,et al.  Heterogeneity in Cancer: Cancer Stem Cells versus Clonal Evolution , 2009, Cell.

[36]  Harikrishna Nakshatri,et al.  CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis , 2006, Breast Cancer Research.

[37]  Zena Werb,et al.  GATA-3 Maintains the Differentiation of the Luminal Cell Fate in the Mammary Gland , 2006, Cell.

[38]  C. Pilarsky,et al.  CD24 expression is a new prognostic marker in breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  John T. Dimos,et al.  A Stem Cell Molecular Signature , 2002, Science.

[40]  Marie-Liesse Asselin-Labat,et al.  Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation , 2007, Nature Cell Biology.

[41]  Charles M. Perou,et al.  Ductal Carcinoma In situ and the Emergence of Diversity during Breast Cancer Evolution , 2008, Clinical Cancer Research.

[42]  Gema Moreno-Bueno,et al.  Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. , 2008, Cancer research.

[43]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[44]  S. Y. Park,et al.  Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. , 2002, Human pathology.

[45]  S. Fox,et al.  Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers , 2009, Nature Medicine.

[46]  Maria Athelogou,et al.  Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  Kornelia Polyak,et al.  Breast cancer: origins and evolution. , 2007, The Journal of clinical investigation.

[48]  E. Thompson,et al.  Mesenchymal to Epithelial Transition in Development and Disease , 2007, Cells Tissues Organs.